N-(cyclopropylmethyl)-8-iodo[1,2,4]triazolo[4,3-a]pyridin-3-amine | 1192744-66-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并吡啶类
• 英文名称: N-(cyclopropylmethyl)-8-iodo[1,2,4]triazolo[4,3-a]pyridin-3-amine
• 英文别名: N-(cyclopropylmethyl)-8-iodo-[1,2,4]triazolo[4,3-a]pyridin-3-amine
• CAS: 1192744-66-3
• 化学式: C₁₀H₁₁IN₄
• 分子量: 314.129
• InChiKey: IZPWDHNSSIVAIV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  42.2
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
  申请人：Laboratorios Almirall, S.A.

  公开号：EP2113503A1

  公开（公告）日：2009-11-04

  This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.

  这项发明涉及具有一般式(I)的新p38丝裂原活化蛋白激酶抑制剂；其制备方法；包含它们的药物组合物；以及它们在治疗中的应用。
• SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS
  申请人：Eastwood Paul Robert

  公开号：US20110046097A1

  公开（公告）日：2011-02-24

  The present disclosure is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.

  本公开涉及具有一般式（I）的p38有丝分裂原活化蛋白激酶的新抑制剂，其制备过程，其制药组合物以及其使用方法。
• NEW SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS
  申请人：Almirall, S.A.

  公开号：EP2280953B1

  公开（公告）日：2012-05-09
• US8450341B2
  申请人：——

  公开号：US8450341B2

  公开（公告）日：2013-05-28
• [EN] NEW SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P39 MITOGEN-ACTIVATED KINASE INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS SUBSTITUÉS INDOLIN-2-ONE ET UTILISATION DE CES DERNIERS EN TANT QU'INHIBITEURS DE KINASE ACTIVÉS PAR LE MITOGÈNE P39
  申请人：ALMIRALL SA

  公开号：WO2009132774A1

  公开（公告）日：2009-11-05

  This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.